The Arkansas Tech University Health and Wellness Center paused distribution of the Johnson and Johnson (Jannsen) COVID-19 vaccine on Tuesday, April 13, in accordance with guidance from the U.S. Centers for Disease Control and Prevention and the U.S. Food and Drug Administration.
The suspension of use for the Johnson and Johnson vaccine was a result of six cases in the United States in which recipients of the Johnson and Johnson COVID-19 vaccine later developed a rare type of blood clot. All suspected cases have been associated in females between the ages of 18 and 48. Additionally, symptoms associated with these blood clots appeared 6-to-13 days after vaccination in all cases.
"Early analysis of the available data suggest that these events are extremely rare," states a message posted to the ATU HWC website. "However, recipients of the Johnson and Johnson vaccine who develop any side effects including severe headache, shortness of breath, abdominal pain or leg pain within three weeks of vaccination should contact their health care provider."
For more information, contact the ATU Health and Wellness Center (479) 968-0329.
COVID-19 vaccines produced by Pfizer and Moderna continue to be available through local pharmacies. Visit https://vaccinefinder.org for more information about vaccine providers.
More details about the suspension of the Johnson and Johnson vaccine are available at www.cdc.gov/media/releases/2021/s0413-JJ-vaccine.html.